In vivo animal conditions implicated that CHR attenuated high fat-induced cardiac injury (through nrf2 dependent antioxidant, antiinflammation), cerebral ischemia/reperfusion injury (through suppression of the NALP3 inflammasome), LPS/D-GalN-caused hepatic injury (through RIP140/NF-κB signaling inhibition), and DOX-induced cardiotoxicity (through antiapoptotic regulation), etc. (Zhang et al., 2014; Jiang et al., 2016; Lian et al., 2017; Lu et al., 2019). The gene discussed is NLRP3; the disease is Cerebral ischemia.